What is Erdheim-Chester disease?
Erdheim-Chester disease (ECD) is a rare disorder in which abnormal immune cells called histiocytes build up in many parts of the body. Histiocytes are a type of white blood cell that normally helps to clear debris and fight infection.
In ECD, these cells collect in tissues such as the long bones of the legs, the area around the kidneys, the aorta, the heart, the brain and the eyes. There they cause inflammation and scarring (fibrosis).
ECD was first described in 1930 by Jakob Erdheim and William Chester. For many years it was considered an inflammatory condition. It is now recognised as a myeloid neoplasm, a type of blood cancer, because most cases are driven by gene changes in the MAPK signalling pathway, such as BRAF V600E (Haroche et al., 2012).
ECD usually affects middle-aged adults. Its course varies widely, from mild bone pain to serious heart, kidney or brain involvement.
Over the past decade, targeted treatments have greatly improved the outlook (Goyal et al., 2020).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of disease | Non-Langerhans cell histiocytosis; a clonal myeloid neoplasm |
| How common | Very rare; around 1,500 cases reported worldwide, though it is probably under-recognised |
| Typical age | Median about 55; rare in children |
| Sex | More common in men (about 3 to 1) |
| Key gene changes | BRAF V600E in about half; MAP2K1 and other MAPK genes in many others |
| Most typical sites | Long bones of the legs, tissue around the kidneys, aorta, heart, pituitary, eyes, brain |
| Main treatments | BRAF inhibitors, MEK inhibitors, interferon-alpha |
| Outlook | Much improved with targeted treatment; depends on heart and brain involvement |
2. How ECD relates to other histiocytoses
ECD belongs to the L group of histiocytic disorders, together with Langerhans cell histiocytosis (LCH) (Emile et al., 2016).
The two diseases share many gene changes, and some people have both, which is called mixed ECD-LCH.
| Feature | ECD | LCH |
|---|---|---|
| Usual age | Adults, mostly over 40 | Mostly children, but also adults |
| Cell markers | CD68+, CD163+; CD1a- and langerin- | CD1a+ and langerin+ |
| Typical bone changes | Hardening (sclerosis) of both leg bones | Punched-out holes in bone |
| Fibrosis | Very common | Less common |
3. Causes and risk factors
ECD starts when blood-forming stem cells or early myeloid cells acquire a gene change that switches on the MAPK pathway. This is a chain of proteins that controls cell growth.
The affected cells mature into histiocytes, which travel to tissues, release inflammatory signals and cause fibrosis.
| Gene change | Approximate frequency |
|---|---|
| BRAF V600E | About 50-60% |
| MAP2K1 | About 20% |
| KRAS, NRAS, ARAF and others | Less common |
| Kinase fusions (ALK, BRAF, NTRK) | Rare |
ECD is not inherited and not infectious. No lifestyle or environmental cause has been identified. About 10% of people also have, or later develop, another myeloid disorder, such as a myeloproliferative neoplasm or myelodysplastic syndrome.
4. How does it look
On scans
Scans are often the first clue to ECD, because several findings are highly typical:
| Finding | What it looks like |
|---|---|
| Sclerosis of the leg bones | Symmetrical hardening of the shafts and ends of the thigh and shin bones, on both sides; seen in about 95% |
| “Hairy kidney” | Shaggy tissue surrounding both kidneys, seen on CT |
| “Coated aorta” | A sleeve of tissue around the aorta, the main artery |
| Right atrium mass | Thickened tissue in the upper right chamber of the heart |
| Fluid around the heart | Pericardial effusion |
| Tissue behind the eyes | Masses in both eye sockets, pushing the eyes forward |
| Brain and pituitary changes | Lesions in the cerebellum, brainstem or pituitary stalk |
A PET-CT scan and a technetium bone scan show increased activity in the leg bones. These scans also help to map the whole extent of the disease.
Visible signs on the body
| Sign | What it looks like |
|---|---|
| Yellow patches on the eyelids | Xanthelasma-like deposits, in about a quarter of patients |
| Bulging eyes | Exophthalmos from tissue behind the eyes |
| Skin lumps | Yellow-brown or red bumps, especially on the face, neck or trunk |
| Swollen legs | From kidney or heart involvement |
Under the microscope
A biopsy shows foamy, lipid-laden histiocytes mixed with inflammatory cells. There are also Touton giant cells (large cells with a ring of nuclei) and fibrosis.
The histiocytes are CD68- and CD163-positive but CD1a-negative and langerin-negative, which distinguishes ECD from LCH.
Organ involvement in more detail
| Organ | How often | What it can cause |
|---|---|---|
| Long bones | About 95% | Bone pain, usually around the knees and ankles |
| Tissue around the kidneys | About 60% | Kidney damage, blocked ureters, high blood pressure |
| Aorta and large arteries | About half | Narrowing of arteries to the kidneys, gut or heart |
| Heart | About 40-50% | Fluid around the heart, rhythm problems, a mass in the right atrium, heart attack |
| Pituitary gland | About a quarter | Diabetes insipidus and other hormone problems |
| Eye sockets | About a quarter | Bulging eyes, double vision, reduced vision |
| Brain and spinal cord | About a third or more | Unsteadiness, speech and swallowing difficulties, memory changes |
| Lungs | About half on scans | Usually mild; sometimes cough or breathlessness |
| Skin | About a quarter | Yellow eyelid patches and skin lumps |
Not everyone has every feature. Some people have disease mainly in the bones, while others have several organs involved at the same time.
5. Symptoms
Symptoms depend on which organs are involved. Many people have several symptoms at once, which can take time to link together.
Common symptoms
- Bone pain, especially in the knees, shins and ankles, in about half of patients
- Excessive thirst and passing large amounts of urine, from diabetes insipidus, which affects about a quarter of patients and often appears years before other symptoms
- Tiredness, fever, night sweats and weight loss
- Bulging eyes, double vision or eye pain
- Yellow patches around the eyes
- Back or flank pain, or reduced kidney function, from tissue around the kidneys and ureters
- Breathlessness or chest pain, from heart or lung involvement
- High blood pressure, if the arteries to the kidneys are narrowed
Brain and nerve symptoms
Involvement of the brain is one of the most serious features of ECD (Diamond et al., 2014):
- Unsteadiness and poor coordination (ataxia)
- Slurred speech and difficulty swallowing
- Changes in memory, mood or behaviour
- Headaches and seizures
Hormone symptoms
Apart from diabetes insipidus, pituitary involvement can lower other hormones. This may cause low sex drive, erectile problems, tiredness or weight changes.
When to seek medical advice
See a doctor if you have persistent bone pain in both legs, unexplained extreme thirst, bulging eyes or new problems with balance or speech.
6. Diagnosis
ECD is often diagnosed several years after the first symptoms. Diagnosis needs a biopsy together with typical scan findings (Goyal et al., 2020).
| Test | Purpose |
|---|---|
| Biopsy | Usually from bone, skin or tissue around the kidneys; confirms ECD histiocytes |
| BRAF V600E testing | Immunostaining and DNA testing of the biopsy |
| Gene panel (next-generation sequencing) | Finds other MAPK changes if BRAF is normal |
| PET-CT scan | Shows all affected areas |
| MRI of the brain and pituitary | Checks for nervous system disease |
| Cardiac MRI and echocardiogram | Looks for heart involvement |
| CT of chest, abdomen and pelvis | Checks lungs, kidneys and aorta |
| Blood tests | Kidney function, inflammation markers (CRP), hormones |
| Water deprivation test | Confirms diabetes insipidus |
| Bone marrow test | If another blood disorder is suspected |
7. Treatment
Almost all people with ECD need treatment because the disease tends to progress. An exception is a small group with mild, symptom-free disease that does not affect vital organs, who may be monitored.
Treatment is best planned at a specialist histiocytosis centre.
Targeted treatment
| Treatment | Who it is for | Main points |
|---|---|---|
| BRAF inhibitors (vemurafenib, dabrafenib) | BRAF V600E-positive ECD | High response rates (Haroche et al., 2013; Diamond et al., 2018) |
| MEK inhibitors (cobimetinib, trametinib) | ECD without BRAF V600E, or BRAF-positive disease if BRAF inhibitors are not tolerated | Work across many MAPK changes |
| Other targeted drugs | Rare fusions, such as ALK or NTRK | Chosen according to the gene change |
These tablets usually shrink lesions and improve symptoms. Treatment is often continued long term, because relapse is common after stopping (Cohen Aubart et al., 2017).
Side effects of targeted treatment
| Drug group | Possible side effects |
|---|---|
| BRAF inhibitors | Skin rash, sensitivity to sunlight, joint pain, tiredness, new skin growths, heart rhythm changes |
| MEK inhibitors | Rash, diarrhoea, swelling, muscle problems, eye problems, heart function changes |
Lower doses are often used in ECD than in melanoma. This helps to reduce side effects while keeping the disease under control.
Other treatments
| Treatment | When it is used |
|---|---|
| Interferon-alpha (often pegylated) | Long-established first treatment, especially when targeted drugs are unavailable |
| Anakinra | For mild disease, mainly bone pain and general symptoms |
| Cladribine | Chemotherapy option for some patients |
| Sirolimus, methotrexate or steroids | In selected cases; steroids alone do not control ECD |
| Hormone replacement | Desmopressin for diabetes insipidus; other hormones as needed |
| Stents | To relieve blockage of the ureters |
| Radiotherapy or surgery | Occasionally, for a single troublesome lesion |
8. Outlook (prognosis)
The outlook for ECD has improved considerably. Older studies reported that fewer than half of patients were alive after 5 years.
With modern diagnosis and targeted treatment, most people now live for many years. However, ECD usually needs long-term management.
| Factor | Effect |
|---|---|
| Response to targeted treatment | Better outlook |
| Brain involvement | Main cause of disability; linked with poorer outcomes |
| Heart involvement | Can be serious and needs close monitoring |
| Kidney involvement | May lead to kidney failure if untreated |
| Associated myeloid disease | Needs its own treatment and follow-up |
Who looks after you
ECD affects many organs, so care is shared by several specialists. A typical team includes a haematologist or oncologist who leads treatment, an endocrinologist for hormone problems, a cardiologist, a nephrologist or urologist for kidney problems, a neurologist and an eye specialist.
A specialist nurse or care coordinator often helps you keep track of appointments and test results.
9. Living with ECD
- Have regular check-ups, often with PET-CT every 3-6 months at first
- Keep a list of all your affected organs, medicines and hormone treatments
- Wear sun protection if you take a BRAF inhibitor
- Carry information about diabetes insipidus and desmopressin if you use it
- Ask about physiotherapy for balance problems
- Contact histiocytosis patient organisations, which offer information and connect people with similar experiences
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is ECD cancer? | It is classified as a myeloid neoplasm, a type of blood cancer, though it grows slowly in many people |
| Is it the same as LCH? | No, but they are closely related and can occur together |
| Will I need treatment for life? | Often, because ECD tends to come back when targeted drugs are stopped |
| Can it be cured? | Long-term control is possible, but cure is uncommon |
| Is it inherited? | No |
| Why did diagnosis take so long? | ECD is very rare and its symptoms overlap with many common conditions, so it is often recognised only when typical scan findings are seen together |
| Can I work and travel? | Many people can, especially once treatment controls the disease; plan travel around scans and carry a medicines list |
11. Questions to ask your care team
- Which organs are affected in my case?
- Does my ECD have a BRAF V600E or other gene change?
- Which treatment do you recommend, and for how long?
- How will we monitor my heart, kidneys and brain?
- Do I need hormone treatment?
- Who should I contact if I develop new symptoms between appointments?
- Are there clinical trials or registries I could join?
Resources
- Goyal, G. et al. (2020) ‘Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era’, Blood, 135(22), pp. 1929-1945.
- Diamond, E.L. et al. (2014) ‘Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease’, Blood, 124(4), pp. 483-492.
- Haroche, J. et al. (2012) ‘High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses’, Blood, 120(13), pp. 2700-2703.
- Haroche, J. et al. (2013) ‘Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation’, Blood, 121(9), pp. 1495-1500.
- Diamond, E.L. et al. (2018) ‘Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study’, JAMA Oncology, 4(3), pp. 384-388.
- Cohen Aubart, F. et al. (2017) ‘Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)’, Blood, 130(11), pp. 1377-1380.
- Emile, J.F. et al. (2016) ‘Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages’, Blood, 127(22), pp. 2672-2681.
- Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms’, Leukemia, 36(7), pp. 1703-1719.
- National Cancer Institute (2026) Langerhans Cell Histiocytosis Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/langerhans/hp/langerhans-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.